Monopar Therapeutics Enters Material Definitive Agreement

Ticker: MNPR · Form: 8-K · Filed: 2025-09-24T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement

TL;DR

Monopar just signed a big deal, details to come.

AI Summary

Monopar Therapeutics Inc. announced on September 23, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Wilmette, IL, filed this 8-K report on September 24, 2025. Specific details of the agreement, including parties involved and financial terms, are not provided in this excerpt.

Why It Matters

This filing indicates a significant new contract or partnership for Monopar Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Monopar Therapeutics?

The filing states that Monopar Therapeutics Inc. entered into a material definitive agreement on September 23, 2025, but the specific details of this agreement are not disclosed in the provided excerpt.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on September 24, 2025.

What is Monopar Therapeutics' state of incorporation?

Monopar Therapeutics Inc. is incorporated in Delaware.

Where are Monopar Therapeutics' principal executive offices located?

Monopar Therapeutics' principal executive offices are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What is the earliest event date reported in this filing?

The earliest event date reported in this filing is September 23, 2025.

From the Filing

0001437749-25-029819.txt : 20250924 0001437749-25-029819.hdr.sgml : 20250924 20250924170606 ACCESSION NUMBER: 0001437749-25-029819 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250923 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250924 DATE AS OF CHANGE: 20250924 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 251339352 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250924_8k.htm FORM 8-K mnpr20250924_8k.htm false 0001645469 0001645469 2025-09-23 2025-09-23     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 23, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd., Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 1.01. Entry into a Material Definitive Agreement.   Underwritten Registered Offering     On September 23, 2025, Monopar Therapeutics Inc., a Delaware corporation (the “ Company ” or “ Monopar ”), entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Barclays Capital Inc. (collectively, the “ Representatives ”), as Representatives of the several underwriters named therein (together with the Representatives, the “ Underwriters ”), pursu

View on Read The Filing